Key facts
- This page summarizes Joseph Marks's Form 4 filing for Augmedix, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Jun 2023, 17:48.
Joseph Marks - 16 Jun 2023 Form 4 Insider Report for Augmedix, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 16 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 16 Jun 2023, 17:48:50 UTC
- Prior SEC filing
- 21 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Ginocchio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Joseph Marks filed Form 4 for Augmedix, Inc. on 16 Jun 2023.
Change
- Previous filing in this sequence was filed on 21 Jun 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AUGX
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +52,632
- Change %
- Price
- Shares after
- 52,632
- Date
- 16 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AUGX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -52,632
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 16 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 52,632
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's common stock.
Footnote F2
On June 16, 2022 (the "Grant Date"), the reporting person was granted 52,632 RSUs which vested in full on the one-year anniversary of the Grant Date.